About Us
About Us » Management Team

Dr. Brian MIN

CEO

  • B.A. from University of California, Berkeley
  • Ph.D. from University of California, Los Angeles
  • 20+ years of experience on biologics development and manufacturing
  • 10+ years experience of antibody discovery in Amgen
  • Experience from target identification/validation to market approval of biologics
  • Played a key role in development of 2 marketed novel biologics
  • Financial impact analysis of drug development and commercialization
  • Experience in IMPD and CTD preparation as well as interaction with regulatory agencies (EMA, FDA, etc.).
  • Led development and manufacturing of all biosimilars in Samsung Bioepis; Scale-up experience to 15,000L bioreactor
  • 4 biosimilar products marketed in US, EU and Korea, 2 entered clinical trial phase III, and 2 entered clinical phase I
  • Core team member that led formation for Samsung Bio companies through joint venture formations

  • Mr. Daniel WANG

    Head of Operation

    • 10+ years' experience in team management, business management, and operations management
    • 14+ years' experience in protein expression, biologics development
    • 2 products entered clinical trial, 3 products entered IND filing

  • Dr. Zhihui ZHAO

    Head of R&D

    • M.D., Ph.D. from Peking University
    • Postdoc at Harvard Medical School, investigation of the molecular mechanisms of glomerulonephritis, lupus nephritis, and genetic disease, ADPKD
    • Assistant Professor of Medicine at Boston University, study of the interaction and immune response between host, ticks, and bacteria
    • Sr. Scientist at Dyax, and Shire Pharmaceuticals
    • Sr. Director at QLB Biotherapeutics Inc., developed monoclonal antibody, and bispecific antibody for immune-oncology therapy
    • With more than 10 years of experience on therapeutic drug development, especially establishing and optimization of antibody, gene and cell therapy platform for immuno-oncology new drug development,  and R&D operations, pre-clinical study, and IND filing

  • Dr. Liusong YIN

    Head of Biologics Discovery

    • B.S. from University of Science and Technology of China, in Cellular and Molecular Immunology
    • Ph.D. and postdoc training from University of Massachusetts Medical School, specialized in antigen presentation, CD4+ T cell epitope selection and antibody responses
    • Previously worked at Pfizer, specialized in immunogenicity of therapeutic biologics
    • 14+ years' experience in immunology, antibody drug discovery and engineering
    • Managed over 500 antibody drug discovery projects with many molecules in clinical phases
    • Published 16 papers in major Immunology, Virology and Biochemistry Journals, cited by more than 300 times
    • Applied over 20 patents in therapeutic monoclonal antibodies, bispecific antibodies, and antibody fusion proteins

  • Weifeng “Frank” ZHANG

    Head of Manufacturing

    • Master of Engineering from McMaster University
    • 20+ years’ in pharma and biotech industries
    • Professional skills in clinical and commercial GMP production, SME in process development, process validation, MSAT and quality engineering areas
    • Multiple successful BLA filings, FDA, EMA and other regulatory audit experiences.
    • Bristol Myers Squibb, Shire

  • Mr. Fredy CHU

    Head of Quality

    • M.S., Analytical Chemistry, Iowa State University
    • 30+ years in pharma/biologics quality management
    • Baxter, Collagen, ChemPartner, PharmaEssentia, Kanghong, Xoma, Fibrogen
    • Responsible for FDA, EMA PAI approvals in US and Asia
    • Multiple successful GMP facility validation in US and Asia
    • Experienced in QA/QC management of multi-site global pharma/biotech
    • Seasoned quality practitioner in drug development, clinical and commercial operations in US, Asia, and EU

  • Dr. Sean LIOUR

    Head of PM & RA

    • Ph.D from Virginia Commonwealth University
    • 10+ years' experience in biologics project management
    • Fountain Biopharma, development of a novel therapeutic antibody project, IND filing and phase I study
    • 2016 joined Shanghai Henlius Biotech, participated in the development and IND/NDA filing of novel antibody drug-conjugate (ADC), novel antibodies and biosimilars.

  • Ms. Lulu LIU

    Head of China BD

    • B.S. from Peking University of Pharmacy
    • EMBA in Fudan University, School of Management
    • 17+ years’ experience in Healthcare, Pharmaceutical, Life Science , and worked at Pfizer, Boehringer-Ingelheim, Medtronic, GE Life Science as local Sales Management and Regional Marketing leadership role
    • Led over 8+ breakthrough launch in China and their long-term strategy plan. Key person of more than 5 global wide strategic projects in Tire I MNC Healthcare companies
    • Led China Biopharma industry understanding Project in 2019 in GE Life Science and illustrated a series of insights for investment transformation